文献速递银屑病与炎症性皮肤病

中重度银屑病生物制剂联合甲氨蝶呤的安全性:BIOBADADERM登记队列研究

Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry.
PubMed 文献 · Br J Dermatol · 2024-01-01

联合MTX未显著增加总体不良事件或严重不良事件风险,但TNF抑制剂联合MTX与胃肠道不良事件发生率升高相关(aIRR 2.50,95% CI 1.57-3.98;P < 0.002)。

要点

  • 生物制剂联合MTX未显著增加总体不良事件或严重不良事件风险。
  • 联合MTX未增加总感染或严重感染数量。
  • TNF抑制剂联合MTX与胃肠道不良事件发生率升高相关(aIRR 2.50)。

核心结论

  • 中重度银屑病患者使用不同类别生物制剂联合MTX相比生物制剂单药,不良事件和严重不良事件风险未显著增加。

主要发现

  • 联合MTX在任何治疗组中均未与不良事件或严重不良事件总体风险的统计学显著增加相关。
  • 联合MTX在任何组中均未观察到总感染数或严重感染数增加。
  • TNF抑制剂联合MTX与胃肠道不良事件发生率升高相关(aIRR 2.50,95% CI 1.57-3.98;P < 0.002)。

关键数值与推荐

  • 采用随机效应泊松回归估计调整发病率比(aIRR)及95%置信区间,覆盖所有不良事件、严重不良事件、感染、严重感染及按系统器官分类的其他不良事件。

临床怎么用

  • 真实世界数据中,生物制剂联合MTX总体安全性未显著劣于单药治疗。
  • TNF抑制剂联合MTX时需关注胃肠道不良事件风险升高。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Safety is an important consideration in decisions on treatment for patients with moderate-to-severe psoriasis and the study of drug safety is the main purpose of the BIOBADADERM registry. The combination of a biologic agent and a conventional systemic drug [generally methotrexate (MTX)] is a common treatment in clinical practice. However, there is a paucity of evidence from real-world practice on the safety of such combination regimens in the treatment of psoriasis. OBJECTIVES: The primary objective of this study was to ascertain whether the use of regimens combining biologic drugs with MTX in the management of moderate-to-severe psoriasis increases the risk of adverse events (AEs) or serious AEs (SAEs). We compared monotherapy using tumour necrosis factor (TNF), interleukin (IL)-17 and IL-23 inhibitors with the use of the same drugs in combination with MTX. METHODS: Using data from the BIOBADADERM registry, we compared biologic monotherapies with therapies that were combined with MTX. We estimated adjusted incidence rate ratios (aIRR) using a random effects Poisson regression with 95% confidence intervals for all AEs, SAEs, infections and serious infections and other AEs by system organ class. RESULTS: We analysed data from 2829 patients and 5441 treatment cycles, a total of 12 853 patient-years. The combination of a biologic with MTX was not associated with statistically significant increases in overall risk of AEs or SAEs in any treatment group. No increase in the total number of infections or serious infections in patients receiving combined therapy was observed for any group. However, treatment with a TNF inhibitor combined with MTX was associated with an increase in the incidence of gastrointestinal AEs (aIRR 2.50, 95% CI 1.57-3.98; P < 0.002). CONCLUSIONS: The risk of AEs and SAEs was not significantly increased in patients with moderate-to-severe psoriasis receiving different classes of biologic drugs combined with MTX compared with those on biologic monotherapy.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Lluch-Galcerá JJ, Carrascosa JM, González-Quesada A, et al. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry. Br J Dermatol. 2024. PMID: 37846976. doi:10.1093/bjd/ljad382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。